Preclinical models show that CSF-1R inhibition reduces TAM infiltration, disrupts M2 programming, and downregulates the CXCL12/CXCR4 axis, an important pathway for tumor cell survival and chemoresistance. Here, CXCR4 is linked to neoplasm.